- Conditions
- Retinitis Pigmentosa
- Interventions
- Sub-Retinal Administration of OCU400-301
- Genetic
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 1,617
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Disease
- Interventions
- Platform for Administering Eye-movement Control Training
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 55 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Aldesleukin
- Drug
- Lead sponsor
- Chiron Corporation
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Toledo, Ohio
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Fovista®, bevacizumab, ranibizumab, aflibercept
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 568 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 81
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more
- Conditions
- Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
- Interventions
- EYE103
- Drug
- Lead sponsor
- EyeBiotech Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Bakersfield, California • Modesto, California + 23 more
- Conditions
- Glaucoma, Vision Impairment and Blindness, Cataract, Diabetic Retinopathy, Eye Diseases
- Interventions
- Enhanced Intervention Using Patient Navigators, Usual Care
- Behavioral · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 749 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetic Retinopathy, Macular Edema
- Interventions
- MK-8748, Aflibercept
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 24
- States / cities
- Glendale, California • Sacramento, California • Denver, Colorado + 21 more
- Conditions
- Central Nervous System/Leptomeningeal Neoplasms
- Interventions
- 131I-omburtamab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cataract
- Interventions
- Omidria
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Central Serous Chorioretinopathy
- Interventions
- Intravitreal Aflibercept Injection
- Drug
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- Retinitis Pigmentosa
- Interventions
- Transcorneal Electrical Stimulation using Okustim device
- Device
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 22 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Interventions
- Optical Coherence Tomography
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Diabetic Retinopathy
- Interventions
- RO7663498
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Glendale, California • Oak Forest, Illinois • Columbus, Ohio + 1 more
- Conditions
- Macular Edema Secondary to Inflammation
- Interventions
- KSI-101, Sham Comparator
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 47 more
- Conditions
- Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion, Retinitis Pigmentosa, Hereditary Macular Degeneration
- Interventions
- CD34+ bone marrow stem cells intravitreal
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Dry Eye Syndromes, Age-Related Macular Degeneration, Omega 3 Index
- Interventions
- OmegaBoost, Nature Made (soft gel), Nature Made (gummy)
- Dietary Supplement
- Lead sponsor
- Western University of Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Pomona, California
- Conditions
- Retinopathy of Prematurity
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 32 Weeks to 40 Weeks
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 11
- States / cities
- Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 8 more
- Conditions
- Intracranial Pressure Increase
- Interventions
- Video ophthalmoscope
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Geographic Atrophy
- Interventions
- APL-2, Sham Procedure
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 67
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 56 more
- Conditions
- Geographic Atrophy, Age Related Macular Degeneration, AMD, Atrophy, Geographic
- Interventions
- ALK-001 oral capsule, Placebo oral capsule
- Drug
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Lakewood, Colorado + 20 more
- Conditions
- Diabetic Retinopathy (DR)
- Interventions
- SaMD intended for the detection of diabetic retinopathy in adults with diabetes., An AI/ML-based Software as a Medical Device (SaMD) for the automated detection of diabetic retinopathy in adults with diabetes.
- Device
- Lead sponsor
- Digital Diagnostics, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Retinal Degeneration, Geographic Atrophy, Macular Atrophy
- Interventions
- Not listed
- Lead sponsor
- Gyroscope Therapeutics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 29 more
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 49
- States / cities
- Scottsdale, Arizona • Encino, California • Fullerton, California + 44 more